Literature DB >> 12924658

Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis.

Miguel R Arguedas1, Thomas G DeLawrence, Brendan M McGuire.   

Abstract

Cirrhosis is associated with decrements in health-related quality of life (HRQOL), but the specific effects of encephalopathy, especially subclinical, on quality of life are incompletely understood. Therefore, the aim of our study was to define the effects of encephalopathy on specific domains of HRQOL in a sample of patients with advanced liver disease. The sample consisted of 160 patients with cirrhosis presenting for liver transplantation evaluation. Health-related quality of life was measured with the Short Form-36 questionnaire. Clinical, demographic, and laboratory data were collected. The presence and degree of encephalopathy was ascertained clinically and by the use of the Reitan trail test. HRQOL scores were compared according to liver disease severity and to the presence and degree of encephalopathy. In addition, scores were compared to US population norms. Data were obtained from 148 patients. Compared to the US general population, the physical and mental component summary scores were lower in patients with cirrhosis. Among patients with cirrhosis, there were no significant differences in the physical and mental component summary scores according to age, gender, ethnicity, and etiology (hepatocellular versus/cholestatic and HCV versus non-HCV). Increasing severity of liver disease (based on the Child-Pugh score), a history of hospitalizations, and a history of ascites were associated with decreased physical component summary scores but not mental component summary scores. Patients with encephalopathy (overt and subclinical) had decreased physical and mental component summary scores compared to patients without encephalopathy. Compared to patients without encephalopathy, those with subclinical encephalopathy had a lower mental component summary score. In conclusion, cirrhosis is associated with a decreased HRQOL, especially at advanced stages. Increased severity of liver disease is associated with decreased physical aspects of quality of life. Overt hepatic encephalopathy negatively affects both physical and mental aspects of quality of life, whereas subclinical encephalopathy affects mainly the mental aspects, independently of liver disease severity.

Entities:  

Mesh:

Year:  2003        PMID: 12924658     DOI: 10.1023/a:1024784327783

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Should quality-of-life needs influence resource allocation?

Authors:  P Fayers; K Bjordal
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

2.  Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance.

Authors:  A Srivastava; R Mehta; S P Rothke; A W Rademaker; A T Blei
Journal:  J Hepatol       Date:  1994-12       Impact factor: 25.083

3.  Health assessment for chronic HCV infection: results of quality of life.

Authors:  R L Carithers; D Sugano; M Bayliss
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1.0.

Authors:  I M Gralnek; R D Hays; A Kilbourne; H R Rosen; E B Keeffe; L Artinian; S Kim; D Lazarovici; D M Jensen; R W Busuttil; P Martin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

5.  Factors associated with poor health-related quality of life of patients with cirrhosis.

Authors:  G Marchesini; G Bianchi; P Amodio; F Salerno; M Merli; C Panella; C Loguercio; G Apolone; M Niero; R Abbiati
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

6.  The impact of diagnosis of hepatitis C virus on quality of life.

Authors:  A J Rodger; D Jolley; S C Thompson; A Lanigan; N Crofts
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

7.  The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation.

Authors:  M De Bona; P Ponton; M Ermani; R M Iemmolo; A Feltrin; P Boccagni; G Gerunda; R Naccarato; G Rupolo; P Burra
Journal:  J Hepatol       Date:  2000-10       Impact factor: 25.083

8.  Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease.

Authors:  Z M Younossi; G Guyatt; M Kiwi; N Boparai; D King
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

9.  Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency: the African American Study of Kidney Disease and Hypertension Trial.

Authors:  John W Kusek; Paul Greene; Shin-Ru Wang; Gerald Beck; Delia West; Kenneth Jamerson; Lawrence Y Agodoa; Marquetta Faulkner; Betty Level
Journal:  Am J Kidney Dis       Date:  2002-03       Impact factor: 8.860

10.  Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  Clin Ther       Date:  1994 Mar-Apr       Impact factor: 3.393

View more
  74 in total

1.  Disease-specific health-related quality of life and its determinants in liver cirrhosis patients in Lithuania.

Authors:  Jolanta Sumskiene; Linas Sumskas; Dalius Petrauskas; Limas Kupcinskas
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  Factors influencing health-related quality of life in chronic liver disease.

Authors:  Abhasnee Sobhonslidsuk; Chatchawan Silpakit; Ronnachai Kongsakon; Patchareeya Satitpornkul; Chaleaw Sripetch; Anya Khanthavit
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 3.  Dietary and nutritional indications in hepatic encephalopathy.

Authors:  Manuela Merli; Oliviero Riggio
Journal:  Metab Brain Dis       Date:  2008-12-04       Impact factor: 3.584

Review 4.  Management of covert hepatic encephalopathy.

Authors:  Abhijeet Waghray; Nisheet Waghray; Kevin Mullen
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

Review 5.  Minimal hepatic encephalopathy impairs quality of life.

Authors:  Swastik Agrawal; Sridharan Umapathy; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-04

6.  Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.

Authors:  Jatinderpal Singh; Barjesh Chander Sharma; Vinod Puri; Sanjeev Sachdeva; Siddharth Srivastava
Journal:  Metab Brain Dis       Date:  2017-01-09       Impact factor: 3.584

Review 7.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

8.  Predicting 30-Day Hospital Readmission Risk in a National Cohort of Patients with Cirrhosis.

Authors:  Jejo D Koola; Sam B Ho; Aize Cao; Guanhua Chen; Amy M Perkins; Sharon E Davis; Michael E Matheny
Journal:  Dig Dis Sci       Date:  2019-09-17       Impact factor: 3.199

9.  Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis.

Authors:  Vincenzo O Palmieri; Daniela Santovito; Francesco Margari; Madia Lozupone; Francesco Minerva; Carla Di Gennaro; Orlando Todarello; Giuseppe Palasciano
Journal:  Clin Exp Med       Date:  2013-12-10       Impact factor: 3.984

10.  Cirrhotic patients have good insight into their daily functional impairment despite prior hepatic encephalopathy: comparison with PROMIS norms.

Authors:  Jasmohan S Bajaj; Melanie B White; Ariel B Unser; Dinesh Ganapathy; Andrew Fagan; Edith A Gavis; Richard K Sterling; Douglas M Heuman; Scott Matherly; Puneet Puri; Arun J Sanyal; Velimir Luketic; Michael Fuchs; Muhammad S Siddiqui; R Todd Stravitz; Binu John; Leroy R Thacker; James B Wade
Journal:  Metab Brain Dis       Date:  2016-06-25       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.